BackInMed Pharmaceuticals Overview

InMed Pharmaceuticals Selling, General & Admin

Selling, General & Admin expenses for INM.

Quarterly SG&A Expenses

$240.12M
↓ 81.93% YoY

As of Mar 31, 2026

Annual SG&A Expenses (TTM)

$9.94B
↑ 4.12% YoY

Trailing 12 months ending Mar 31, 2026

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin